Enlaza Therapeutics
LA JOLLA, California · Biotechnology, Healthcare, Health Care
Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-Lock™ platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.
Key facts
- Headquarters
- LA JOLLA, California
- Employees
- 55
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Private
- Website
- enlazatx.com
- Company page
Recent activity at Enlaza Therapeutics
Enlaza Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Venture | $15.0M |
| Aug 2024 | Venture | $84.0M |
| Nov 2022 | Venture | $35.3M |
| Jun 2021 | Venture | Undisclosed |
| Mar 2021 | Venture | $35.3M |
Leadership
- Marcos Milla, Director
- James Topper, Director
- Shelley Chu, Director
- Jay Lichter, Director
- Sergio Duron, Executive Officer, Director
- Sergio Duron, Executive Officer, Director
- Jay Lichter, Director
- Shelley Chu, Director
- James Topper, Director
- Marcos Milla, Director
- Sergio Duron, Executive Officer, Director
- Jay Lichter, Director
Verified email and direct lines for Enlaza Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Enlaza Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Enlaza Therapeutics in the news
- Press Release Service: Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases - CRISPR Medicine News (Sep 02, 2025)
- Two Biomedical Firms Begin Drug Development Collaboration Centered on Covalent Biologics - DocWireNews (Sep 04, 2025)
- Enlaza Therapeutics Forms $2.4 Billion Collaboration with Vertex Pharmaceuticals - Pharmaceutical Executive (Sep 03, 2025)
- Press Release Service: Enlaza Therapeutics Appoints Jeffrey Leiden, M.D., Ph.D., as a Key Advisor - CRISPR Medicine News (Jun 18, 2024)
Companies similar to Enlaza Therapeutics
- Beyond Air · Biotechnology, Healthcare, Health Care
- Omniscient Neurotechnology · Biotechnology, Healthcare, Health Care
- Pharmazz · Biotechnology, Healthcare, Health Care
- Avalyn · Biotechnology, Healthcare, Health Care
- Shape Memory Medical · Biotechnology, Healthcare, Health Care
About Enlaza Therapeutics: questions and answers
What does Enlaza Therapeutics do?
Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-Lock™ platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.
Where is Enlaza Therapeutics headquartered?
Enlaza Therapeutics is headquartered in LA JOLLA, California.
How many employees does Enlaza Therapeutics have?
Enlaza Therapeutics has about 55 employees.
Has Enlaza Therapeutics raised funding?
Yes. Fundz has recorded 5 funding events for Enlaza Therapeutics. The most recent, $15.0M, was in Sep 2025.
What is the latest news on Enlaza Therapeutics?
On Sep 11, 2025, Enlaza Therapeutics
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy